Cambridge Crossing
Update
07/02/21
Sanofi to Open mRNA Development Center at Cambridge Crossing
French drug developer Sanofi has announced it is investing nearly $480 million developing a vaccines mRNA "Center of Excellence" at campuses in Cambridge Crossing and Lyon, France. The research hubs will be used to trial and develop vaccines similar to their COVID-19 product.
Upon completion, Cambridge Crossing will feature 2.1 million square feet of state-of-the-art science and technology office space, 2.4 million square feet of residential space with 2,400 residential units.
Search BLDUP
Search
BLDUP
for news, projects, and companies to find the information that pushes your business forward.
